King Saud University’s Medical City took part in recent worldwide research, the results of which were published in the British Medical Journal The (BMJ) this week.
The goal of the comparative scientific investigation was to determine the impact of blood thinners (heparin medicines), which are commonly used in hospitals to reduce the consequences of the growing coronavirus illness.
The Saudi research team’s leader, Dr. Mosaed Bin Homoud said that the research is based upon results come from those people infected with the virus, which causes severe and hazardous consequences such as arterial and venous thrombosis.
According to Dr. Al-Hamza, the BMJ-published study compared two groups of patients, one of whom received the usual preventive doses for hospital patients and the other of whom received the high doses used to treat patients after they had clots in general. They found that patients in the high-dose group died less than patients in the preventive doses for medium infected cases, as well as those with a high amount of (D-dimer), a protein that aids in the production of clots.
He went on to say that the study facilities in the Kingdom comprised King Saud University Medical City, King Faisal Specialist Hospital in Riyadh, and King Fahd Medical City in Riyadh, where 148 patients took part, accounting for one-third of the total number of participants in the study worldwide.
Dr. Al-Hamza appreciated the research team’s efforts, emphasizing that their involvement helps the work of those in charge of medical scientific research.
The BMJ-published study’s noteworthy findings might lead to a change in treatment methods for intermediate cases infected with the virus, which are individuals who are hospitalized owing to a lack of oxygen.